

Supplementary Materials for  
Consolidated Financial Results for  
Fiscal Year 2019. 12 (IFRS)

Innovation all for the patients



CHUGAI PHARMACEUTICAL CO., LTD.

Roche A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
3. Exchange rates used for each period are as follows.

### QTR

(Yen)

		Actual*				Actual*			
		FY2018				FY2019			
		1-3	4-6	7-9	10-12	1-3	4-6	7-9	10-12
		QTR	QTR	QTR	QTR	QTR	QTR	QTR	QTR
CHF		114.33	110.77	113.32	113.33	110.52	109.66	108.89	109.82
EUR		133.17	130.06	129.66	128.72	125.17	123.53	119.35	120.35
USD		108.40	109.08	111.47	112.84	110.18	109.96	107.33	108.72
SGD		82.16	81.78	81.51	82.04	81.32	80.66	78.05	79.75

\*Market average exchange rate

### YTD

	Actual*	Actual*				Actual*				Assumption
	FY2017	FY2018				FY2019				FY2020
	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	1-12
	Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year	Full-year
CHF	113.90	114.33	112.52	112.79	112.92	110.52	110.09	109.69	109.72	110.00
EUR	126.39	133.17	131.59	130.93	130.36	125.17	124.34	122.66	122.08	121.00
USD	112.17	108.40	108.74	109.65	110.45	110.18	110.07	109.15	109.05	107.00
SGD	81.22	82.16	81.97	81.81	81.87	81.32	80.99	80.00	79.94	80.00

\*Market average exchange rate

### Period-end

	Actual	Actual				Actual			
	FY2017	FY2018				FY2019			
	31 Dec.	31 Mar.	30 Jun.	30 Sep.	31 Dec.	31 Mar.	30 Jun.	30 Sep.	31 Dec.
CHF	115.35	111.67	110.78	116.01	112.03	111.11	110.39	108.93	112.31
EUR	134.82	131.49	127.83	131.98	126.13	124.15	122.56	118.07	121.93
USD	112.89	106.83	110.50	113.38	110.28	110.64	107.80	107.94	108.88
SGD	84.39	81.43	80.79	82.88	80.70	81.56	79.64	78.12	80.72

## Reconciliation of IFRS results to Core results

(Billions of yen)

	FY2018				FY2019			
	1-12				1-12			
	IFRS results	Intangible assets	Others	Core results	IFRS results	Intangible assets	Others	Core results
Revenues	579.8	-	-	579.8	686.2	-	-	686.2
Sales	527.8	-	-	527.8	588.9	-	-	588.9
Royalties and other operating income	51.9	-	-	51.9	97.3	-	-	97.3
Cost of sales	(262.8)	1.0	-	(261.9)	(266.1)	1.0	-	(265.1)
Gross profit	316.9	1.0	-	317.9	420.1	1.0	-	421.1
Operating expenses	(192.6)	5.0	-	(187.6)	(209.5)	2.8	10.5	(196.2)
Marketing and distribution	(73.7)	-	-	(73.7)	(77.2)	-	3.7	(73.5)
Research and development	(99.2)	5.0	-	(94.2)	(107.9)	2.8	3.0	(102.1)
General and administration	(19.7)	-	-	(19.7)	(24.4)	-	3.8	(20.6)
Operating profit	124.3	6.0	-	130.3	210.6	3.8	10.5	224.9
Financing costs	(0.1)	-	-	(0.1)	(0.1)	-	-	(0.1)
Other financial income (expense)	0.4	-	-	0.4	0.5	-	-	0.5
Other expense	(3.2)	-	-	(3.2)	(3.1)	-	-	(3.1)
Profit before taxes	121.4	6.0	-	127.5	207.9	3.8	10.5	222.2
Income taxes	(28.4)	(1.8)	-	(30.2)	(50.3)	(1.1)	(3.1)	(54.6)
Net income	93.1	4.2	-	97.3	157.6	2.6	7.4	167.6
Attributable to								
Chugai shareholders	92.5	4.2	-	96.7	157.6	2.6	7.4	167.6
Non-controlling interests	0.6	-	-	0.6	-	-	-	-

## Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results, and are consistent with the Core concept disclosed by Roche. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.

The table above shows the reconciliation of IFRS results into Core results. The detail is as below.

## Intangible assets

Amortization (1.2 billion yen in 2018 and 1.2 billion yen in 2019)

Impairment (4.8 billion yen in 2018 and 2.6 billion yen in 2019)

## Others

Early retirement incentive program (5.1 billion yen in 2019)

Restructuring expenses (2.8 billion yen in 2019)

Legal income and expenses (2.6 billion yen in 2019)

## IFRS results (QTR)

(Billions of yen)

	Actual FY2018				Actual FY2019							
	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
Revenues	147.4	137.7	141.3	153.3	154.3	+4.7	166.0	+20.6	188.6	+33.5	177.3	+15.7
Sales	124.7	130.8	133.1	139.1	137.7	+10.4	144.7	+10.6	158.0	+18.7	148.4	+6.7
Domestic	92.9	98.3	99.6	109.1	99.3	+6.9	110.7	+12.6	114.4	+14.9	113.1	+3.7
Overseas	31.9	32.6	33.5	30.0	38.4	+20.4	34.0	+4.3	43.6	+30.1	35.3	+17.7
Royalties and other operating income	22.7	6.8	8.2	14.2	16.6	(26.9)	21.3	+213.2	30.5	+272.0	28.9	+103.5
Royalty and profit-sharing income	5.0	5.1	5.7	8.3	13.7	+174.0	16.6	+225.5	18.5	+224.6	27.7	+233.7
Other operating income	17.7	1.8	2.5	5.9	2.9	(83.6)	4.7	+161.1	12.0	+380.0	1.1	(81.4)
Cost of sales	(63.8)	(65.2)	(65.9)	(67.8)	(63.9)	+0.2	(64.1)	(1.7)	(74.0)	+12.3	(64.1)	(5.5)
(% of Sales)	51.2	49.8	49.5	48.7	46.4	-	44.3	-	46.8	-	43.2	-
Gross profit	83.6	72.5	75.4	85.5	90.4	+8.1	101.9	+40.6	114.5	+51.9	113.3	+32.5
(% of Revenues)	56.7	52.7	53.4	55.8	58.6	-	61.4	-	60.7	-	63.9	-
Operating expenses	(45.2)	(44.2)	(44.0)	(59.1)	(44.3)	(2.0)	(53.0)	+19.9	(48.7)	+10.7	(63.5)	+7.4
(% of Revenues)	30.7	32.1	31.1	38.6	28.7	-	31.9	-	25.8	-	35.8	-
Marketing and distribution	(15.9)	(17.3)	(17.2)	(23.3)	(15.4)	(3.1)	(20.4)	+17.9	(18.6)	+8.1	(22.8)	(2.1)
(% of Revenues)	10.8	12.6	12.2	15.2	10.0	-	12.3	-	9.9	-	12.9	-
Research and development	(25.1)	(23.5)	(22.3)	(28.3)	(25.1)	0.0	(26.7)	+13.6	(25.1)	+12.6	(31.0)	+9.5
(% of Revenues)	17.0	17.1	15.8	18.5	16.3	-	16.1	-	13.3	-	17.5	-
General and administration	(4.3)	(3.5)	(4.4)	(7.5)	(3.7)	(14.0)	(5.9)	+68.6	(5.1)	+15.9	(9.7)	+29.3
(% of Revenues)	2.9	2.5	3.1	4.9	2.4	-	3.6	-	2.7	-	5.5	-
Operating profit	38.4	28.2	31.3	26.4	46.1	+20.1	49.0	+73.8	65.8	+110.2	49.7	+88.3
(% of Revenues)	26.1	20.5	22.2	17.2	29.9	-	29.5	-	34.9	-	28.0	-
Financing costs	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0
Other financial income (expense)	(0.1)	0.1	(0.1)	0.5	0.2	-	0.1	0.0	(0.3)	+200.0	0.5	0.0
Other expense	(0.6)	(0.9)	(0.6)	(1.1)	(0.8)	+33.3	(0.7)	(22.2)	(0.7)	+16.7	(0.9)	(18.2)
Profit before taxes	37.7	27.3	30.6	25.8	45.4	+20.4	48.4	+77.3	64.8	+111.8	49.3	+91.1
(% of Revenues)	25.6	19.8	21.7	16.8	29.4	-	29.2	-	34.4	-	27.8	-
Income taxes	(9.5)	(6.4)	(8.8)	(3.6)	(10.4)	+9.5	(14.1)	+120.3	(16.7)	+89.8	(9.2)	+155.6
Net income	28.2	20.9	21.8	22.2	35.0	+24.1	34.2	+63.6	48.1	+120.6	40.2	+81.1
(% of Revenues)	19.1	15.2	15.4	14.5	22.7	-	20.6	-	25.5	-	22.7	-
Attributable to												
Chugai shareholders	27.9	20.8	21.7	22.1	35.0	+25.4	34.2	+64.4	48.1	+121.7	40.2	+81.9
Non-controlling interests	0.3	0.1	0.2	0.1	-	-	-	-	-	-	-	-
Earnings per share												
Basic (yen)	51.00	38.00	39.60	40.48	64.01	+25.5	62.53	+64.6	87.94	+122.1	73.36	+81.2
Diluted (yen)	50.91	37.94	39.54	40.41	63.91	+25.5	62.44	+64.6	87.82	+122.1	73.26	+81.3

Other financial income (expense) includes net amount of FX related gains/losses.

"Sales of Tamiflu", which was disclosed separately up to FY 2018, is included in "Sales of Domestic" from the first quarter in FY 2019.

"Royalties and other operating income" is disclosed separately as "Royalty and profit-sharing income" and "Other operating income" from the first quarter in FY 2019.

## IFRS results (YTD)

(Billions of yen)

	Actual	Actual				Actual							
	FY2017	FY2018				FY2019							
	1-12	1-3	1-6	1-9	1-12	1-3	Change	1-6	Change	1-9	Change	1-12	Change
	YTD	YTD	YTD	YTD	YTD	YTD	(%)	YTD	(%)	YTD	(%)	YTD	(%)
Revenues	534.2	147.4	285.1	426.4	579.8	154.3	+4.7	320.3	+12.3	508.9	+19.3	686.2	+18.4
Sales	499.3	124.7	255.6	388.7	527.8	137.7	+10.4	282.4	+10.5	440.5	+13.3	588.9	+11.6
Domestic	405.3	92.9	191.1	290.8	399.9	99.3	+6.9	210.0	+9.9	324.4	+11.6	437.6	+9.4
Overseas	94.0	31.9	64.5	97.9	127.9	38.4	+20.4	72.4	+12.2	116.0	+18.5	151.3	+18.3
Royalties and other operating income	34.9	22.7	29.5	37.7	51.9	16.6	(26.9)	37.9	+28.5	68.4	+81.4	97.3	+87.5
Royalty and profit-sharing income	17.2	5.0	10.1	15.8	24.1	13.7	+174.0	30.2	+199.0	48.8	+208.9	76.5	+217.4
Other operating income	17.7	17.7	19.5	21.9	27.9	2.9	(83.6)	7.6	(61.0)	19.6	(10.5)	20.8	(25.4)
Cost of sales	(254.2)	(63.8)	(129.1)	(195.0)	(262.8)	(63.9)	+0.2	(128.0)	(0.9)	(202.0)	+3.6	(266.1)	+1.3
(% of Sales)	50.9	51.2	50.5	50.2	49.8	46.4	-	45.3	-	45.9	-	45.2	-
Gross profit	280.0	83.6	156.1	231.4	316.9	90.4	+8.1	192.3	+23.2	306.9	+32.6	420.1	+32.6
(% of Revenues)	52.4	56.7	54.8	54.3	54.7	58.6	-	60.0	-	60.3	-	61.2	-
Operating expenses	(181.1)	(45.2)	(89.5)	(133.5)	(192.6)	(44.3)	(2.0)	(97.3)	+8.7	(146.0)	+9.4	(209.5)	+8.8
(% of Revenues)	33.9	30.7	31.4	31.3	33.2	28.7	-	30.4	-	28.7	-	30.5	-
Marketing and distribution	(72.8)	(15.9)	(33.2)	(50.4)	(73.7)	(15.4)	(3.1)	(35.8)	+7.8	(54.4)	+7.9	(77.2)	+4.7
(% of Revenues)	13.6	10.8	11.6	11.8	12.7	10.0	-	11.2	-	10.7	-	11.3	-
Research and development	(92.9)	(25.1)	(48.5)	(70.9)	(99.2)	(25.1)	0.0	(51.8)	+6.8	(76.9)	+8.5	(107.9)	+8.8
(% of Revenues)	17.4	17.0	17.0	16.6	17.1	16.3	-	16.2	-	15.1	-	15.7	-
General and administration	(15.3)	(4.3)	(7.8)	(12.2)	(19.7)	(3.7)	(14.0)	(9.6)	+23.1	(14.7)	+20.5	(24.4)	+23.9
(% of Revenues)	2.9	2.9	2.7	2.9	3.4	2.4	-	3.0	-	2.9	-	3.6	-
Operating profit	98.9	38.4	66.6	97.9	124.3	46.1	+20.1	95.1	+42.8	160.9	+64.4	210.6	+69.4
(% of Revenues)	18.5	26.1	23.4	23.0	21.4	29.9	-	29.7	-	31.6	-	30.7	-
Financing costs	(0.1)	(0.0)	(0.1)	(0.1)	(0.1)	(0.0)	0.0	(0.1)	0.0	(0.1)	0.0	(0.1)	0.0
Other financial income (expense)	(0.1)	(0.1)	0.0	(0.1)	0.4	0.2	-	0.3	-	0.0	-	0.5	+25.0
Other expense	(1.7)	(0.6)	(1.5)	(2.1)	(3.2)	(0.8)	+33.3	(1.5)	0.0	(2.2)	+4.8	(3.1)	(3.1)
Profit before taxes	97.0	37.7	65.0	95.6	121.4	45.4	+20.4	93.8	+44.3	158.6	+65.9	207.9	+71.3
(% of Revenues)	18.2	25.6	22.8	22.4	20.9	29.4	-	29.3	-	31.2	-	30.3	-
Income taxes	(23.5)	(9.5)	(15.9)	(24.8)	(28.4)	(10.4)	+9.5	(24.5)	+54.1	(41.2)	+66.1	(50.3)	+77.1
Net income	73.5	28.2	49.0	70.9	93.1	35.0	+24.1	69.3	+41.4	117.4	+65.6	157.6	+69.3
(% of Revenues)	13.8	19.1	17.2	16.6	16.1	22.7	-	21.6	-	23.1	-	23.0	-
Attributable to													
Chugai shareholders	72.7	27.9	48.7	70.3	92.5	35.0	+25.4	69.3	+42.3	117.4	+67.0	157.6	+70.4
Non-controlling interests	0.8	0.3	0.4	0.5	0.6	-	-	-	-	-	-	-	-
Earnings per share													
Basic (yen)	133.04	51.00	89.00	128.60	169.08	64.01	+25.5	126.54	+42.2	214.48	+66.8	287.84	+70.2
Diluted (yen)	132.83	50.91	88.85	128.39	168.80	63.91	+25.5	126.35	+42.2	214.17	+66.8	287.43	+70.3

Other financial income (expense) includes net amount of FX related gains/losses.

"Sales of Tamiflu", which was disclosed separately up to FY 2018, is included in "Sales of Domestic" from the first quarter in FY 2019.

"Royalties and other operating income" is disclosed separately as "Royalty and profit-sharing income" and "Other operating income" from the first quarter in FY 2019.

## Core results (QTR)

(Billions of yen)

	Actual				Actual							
	FY2018				FY2019							
	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
Revenues	147.4	137.7	141.3	153.3	154.3	+4.7	166.0	+20.6	188.6	+33.5	177.3	+15.7
Sales	124.7	130.8	133.1	139.1	137.7	+10.4	144.7	+10.6	158.0	+18.7	148.4	+6.7
Domestic	92.9	98.3	99.6	109.1	99.3	+6.9	110.7	+12.6	114.4	+14.9	113.1	+3.7
Overseas	31.9	32.6	33.5	30.0	38.4	+20.4	34.0	+4.3	43.6	+30.1	35.3	+17.7
Royalties and other operating income	22.7	6.8	8.2	14.2	16.6	(26.9)	21.3	+213.2	30.5	+272.0	28.9	+103.5
Royalty and profit-sharing income	5.0	5.1	5.7	8.3	13.7	+174.0	16.6	+225.5	18.5	+224.6	27.7	+233.7
Other operating income	17.7	1.8	2.5	5.9	2.9	(83.6)	4.7	+161.1	12.0	+380.0	1.1	(81.4)
Cost of sales	(63.5)	(65.1)	(65.7)	(67.6)	(63.7)	+0.3	(63.9)	(1.8)	(73.8)	+12.3	(63.8)	(5.6)
(% of Sales)	50.9	49.8	49.4	48.6	46.3	-	44.2	-	46.7	-	43.0	-
Gross profit	83.9	72.6	75.6	85.8	90.6	+8.0	102.1	+40.6	114.8	+51.9	113.5	+32.3
(% of Revenues)	56.9	52.7	53.5	56.0	58.7	-	61.5	-	60.9	-	64.0	-
Operating expenses	(41.1)	(43.8)	(44.0)	(58.7)	(42.7)	+3.9	(46.5)	+6.2	(47.3)	+7.5	(59.7)	+1.7
(% of Revenues)	27.9	31.8	31.1	38.3	27.7	-	28.0	-	25.1	-	33.7	-
Marketing and distribution	(15.9)	(17.3)	(17.2)	(23.3)	(15.4)	(3.1)	(17.5)	+1.2	(18.0)	+4.7	(22.5)	(3.4)
(% of Revenues)	10.8	12.6	12.2	15.2	10.0	-	10.5	-	9.5	-	12.7	-
Research and development	(20.9)	(23.0)	(22.3)	(27.9)	(23.6)	+12.9	(24.3)	+5.7	(24.2)	+8.5	(30.0)	+7.5
(% of Revenues)	14.2	16.7	15.8	18.2	15.3	-	14.6	-	12.8	-	16.9	-
General and administration	(4.3)	(3.5)	(4.4)	(7.5)	(3.7)	(14.0)	(4.7)	+34.3	(5.1)	+15.9	(7.1)	(5.3)
(% of Revenues)	2.9	2.5	3.1	4.9	2.4	-	2.8	-	2.7	-	4.0	-
Operating profit	42.8	28.8	31.6	27.1	47.9	+11.9	55.7	+93.4	67.5	+113.6	53.8	+98.5
(% of Revenues)	29.0	20.9	22.4	17.7	31.0	-	33.6	-	35.8	-	30.3	-
Financing costs	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0
Other financial income (expense)	(0.1)	0.1	(0.1)	0.5	0.2	-	0.1	0.0	(0.3)	+200.0	0.5	0.0
Other expense	(0.6)	(0.9)	(0.6)	(1.1)	(0.8)	+33.3	(0.7)	(22.2)	(0.7)	+16.7	(0.9)	(18.2)
Profit before taxes	42.1	28.0	30.9	26.5	47.2	+12.1	55.1	+96.8	66.5	+115.2	53.4	+101.5
(% of Revenues)	28.6	20.3	21.9	17.3	30.6	-	33.2	-	35.3	-	30.1	-
Income taxes	(10.9)	(6.6)	(8.9)	(3.8)	(10.9)	0.0	(16.2)	+145.5	(17.2)	+93.3	(10.3)	+171.1
Net income	31.2	21.3	22.0	22.7	36.3	+16.3	38.9	+82.6	49.3	+124.1	43.2	+90.3
(% of Revenues)	21.2	15.5	15.6	14.8	23.5	-	23.4	-	26.1	-	24.4	-
Attributable to												
Chugai shareholders	31.0	21.2	21.8	22.6	36.3	+17.1	38.9	+83.5	49.3	+126.1	43.2	+91.2
Non-controlling interests	0.3	0.1	0.2	0.1	-	-	-	-	-	-	-	-
Core earnings per share (diluted) (yen)	56.52	38.75	39.87	41.28	66.15	+17.0	70.95	+83.1	89.95	+125.6	78.75	+90.8

Please see page 1 "Reconciliation of IFRS results to Core results" for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

"Sales of Tamiflu", which was disclosed separately up to FY 2018, is included in "Sales of Domestic" from the first quarter in FY 2019.

"Royalties and other operating income" is disclosed separately as "Royalty and profit-sharing income" and "Other operating income" from the first quarter in FY 2019.

## Core results (YTD)

(Billions of yen)

	Actual	Actual				Actual								Forecast (Jan 30th announced)	
	FY2017	FY2018				FY2019								FY2020	
	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-12	Change (%)
	YTD	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		YTD	
Revenues	534.2	147.4	285.1	426.4	579.8	154.3	+4.7	320.3	+12.3	508.9	+19.3	686.2	+18.4	740.0	+7.8
Sales	499.3	124.7	255.6	388.7	527.8	137.7	+10.4	282.4	+10.5	440.5	+13.3	588.9	+11.6	580.0	(1.5)
Domestic	405.3	92.9	191.1	290.8	399.9	99.3	+6.9	210.0	+9.9	324.4	+11.6	437.6	+9.4	411.6	(5.9)
Overseas	94.0	31.9	64.5	97.9	127.9	38.4	+20.4	72.4	+12.2	116.0	+18.5	151.3	+18.3	168.4	+11.3
Royalties and other operating income	34.9	22.7	29.5	37.7	51.9	16.6	(26.9)	37.9	+28.5	68.4	+81.4	97.3	+87.5	160.0	+64.4
Royalty and profit-sharing income	17.2	5.0	10.1	15.8	24.1	13.7	+174.0	30.2	+199.0	48.8	+208.9	76.5	+217.4	141.0	+84.3
Other operating income	17.7	17.7	19.5	21.9	27.9	2.9	(83.6)	7.6	(61.0)	19.6	(10.5)	20.8	(25.4)	19.0	(8.7)
Cost of sales	(252.9)	(63.5)	(128.6)	(194.3)	(261.9)	(63.7)	+0.3	(127.5)	(0.9)	(201.3)	+3.6	(265.1)	+1.2	(252.0)	(4.9)
(% of Sales)	50.7	50.9	50.3	50.0	49.6	46.3	-	45.1	-	45.7	-	45.0	-	43.4	-
Gross profit	281.3	83.9	156.6	232.1	317.9	90.6	+8.0	192.7	+23.1	307.5	+32.5	421.1	+32.5	488.0	+15.9
(% of Revenues)	52.7	56.9	54.9	54.4	54.8	58.7	-	60.2	-	60.4	-	61.4	-	65.9	-
Operating expenses	(178.1)	(41.1)	(84.9)	(128.9)	(187.6)	(42.7)	+3.9	(89.2)	+5.1	(136.5)	+5.9	(196.2)	+4.6	(213.0)	+8.6
(% of Revenues)	33.3	27.9	29.8	30.2	32.4	27.7	-	27.8	-	26.8	-	28.6	-	28.8	-
Marketing and distribution	(72.8)	(15.9)	(33.2)	(50.4)	(73.7)	(15.4)	(3.1)	(32.9)	(0.9)	(51.0)	+1.2	(73.5)	(0.3)		
(% of Revenues)	13.6	10.8	11.6	11.8	12.7	10.0	-	10.3	-	10.0	-	10.7	-		
Research and development	(88.9)	(20.9)	(44.0)	(66.3)	(94.2)	(23.6)	+12.9	(47.9)	+8.9	(72.0)	+8.6	(102.1)	+8.4	(115.0)	+12.6
(% of Revenues)	16.6	14.2	15.4	15.5	16.2	15.3	-	15.0	-	14.1	-	14.9	-	15.5	-
General and administration	(16.3)	(4.3)	(7.8)	(12.2)	(19.7)	(3.7)	(14.0)	(8.4)	+7.7	(13.5)	+10.7	(20.6)	+4.6		
(% of Revenues)	3.1	2.9	2.7	2.9	3.4	2.4	-	2.6	-	2.7	-	3.0	-		
Operating profit	103.2	42.8	71.6	103.3	130.3	47.9	+11.9	103.5	+44.6	171.1	+65.6	224.9	+72.6	275.0	+22.3
(% of Revenues)	19.3	29.0	25.1	24.2	22.5	31.0	-	32.3	-	33.6	-	32.8	-	37.2	-
Financing costs	(0.1)	(0.0)	(0.1)	(0.1)	(0.1)	(0.0)	0.0	(0.1)	0.0	(0.1)	0.0	(0.1)	0.0		
Other financial income (expense)	(0.1)	(0.1)	0.0	(0.1)	0.4	0.2	-	0.3	-	0.0	-	0.5	+25.0		
Other expense	(1.7)	(0.6)	(1.5)	(2.1)	(3.2)	(0.8)	+33.3	(1.5)	0.0	(2.2)	+4.8	(3.1)	(3.1)		
Profit before taxes	101.3	42.1	70.1	101.0	127.5	47.2	+12.1	102.3	+45.9	168.8	+67.1	222.2	+74.3		
(% of Revenues)	19.0	28.6	24.6	23.7	22.0	30.6	-	31.9	-	33.2	-	32.4	-		
Income taxes	(24.5)	(10.9)	(17.5)	(26.4)	(30.2)	(10.9)	0.0	(27.1)	+54.9	(44.3)	+67.8	(54.6)	+80.8		
Net income	76.7	31.2	52.6	74.6	97.3	36.3	+16.3	75.1	+42.8	124.5	+66.9	167.6	+72.3	201.0	+19.9
(% of Revenues)	14.4	21.2	18.4	17.5	16.8	23.5	-	23.4	-	24.5	-	24.4	-	27.2	-
Attributable to															
Chugai shareholders	75.9	31.0	52.2	74.0	96.7	36.3	+17.1	75.1	+43.9	124.5	+68.2	167.6	+73.3		
Non-controlling interests	0.8	0.3	0.4	0.5	0.6	-	-	-	-	-	-	-	-		
Weighted average number of shares in issue used to calculate diluted earnings per share (Millions of shares)	547	548	548	548	548	548	0.0	548	0.0	548	0.0	548	0.0		
Core earnings per share (diluted) (yen)	138.68	56.52	95.27	135.14	176.42	66.15	+17.0	137.11	+43.9	227.06	+68.0	305.80	+73.3	122.00	-
Core payout ratio (%)	44.7				48.7								45.8	41.0	-
Dividend per share (Full year) (yen)	62				86								140	-	-
Dividend per share (Year end) (yen)	33				55								92	25	-
Dividend per share (Half year) (yen)	29				31								48	75	-

Please see page 1 "Reconciliation of IFRS results to Core results" for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

"Sales of Tamiflu", which was disclosed separately up to FY 2018, is included in "Sales of Domestic" from the first quarter in FY 2019.

"Royalties and other operating income" is disclosed separately as "Royalty and profit-sharing income" and "Other operating income" from the first quarter in FY 2019.

Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") has resolved to implement a three-for-one stock split of its common stock. The dividend forecast for the fiscal year ending December 31, 2020

presents the amount prior to the stock split for the end of the second quarter and the amount after the stock split for the end of the fiscal year. The annual dividends per share forecast is not stated because the amounts cannot be simply combined due to the implementation of the stock split. When calculated based on the assumption of no stock split, the year-end dividend is ¥75 and the annual dividend per share is ¥150.

Core EPS for the fiscal year ending December 31, 2020 (forecast) presents the amount after the stock split. The percentage change from the same period of the previous fiscal year for Core EPS is not presented because a simple comparison cannot be made.

## Statements of revenues (QTR)

(Billions of yen)

	Actual FY2018				Actual FY2019							
	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
<b>Sales</b>	124.7	130.8	133.1	139.1	137.7	+10.4	144.7	+10.6	158.0	+18.7	148.4	+6.7
<b>Domestic</b>	92.9	98.3	99.6	109.1	99.3	+6.9	110.7	+12.6	114.4	+14.9	113.1	+3.7
<b>Oncology</b>	48.6	57.0	57.7	62.3	52.0	+7.0	62.5	+9.6	65.1	+12.8	60.8	(2.4)
Avastin	21.0	24.4	24.1	26.1	21.4	+1.9	25.3	+3.7	26.3	+9.1	22.6	(13.4)
Perjeta	3.2	3.8	3.9	5.2	5.6	+75.0	7.6	+100.0	8.8	+125.6	8.7	+67.3
Herceptin	6.8	7.0	6.8	7.5	6.2	(8.8)	7.4	+5.7	6.8	0.0	6.4	(14.7)
Alecensa	4.0	5.4	5.3	5.9	4.9	+22.5	6.2	+14.8	6.1	+15.1	5.8	(1.7)
Tecentriq	-	1.7	3.3	4.1	3.7	-	4.6	+170.6	5.5	+66.7	6.9	+68.3
Rituxan	6.2	5.7	5.2	4.2	3.1	(50.0)	3.3	(42.1)	2.8	(46.2)	2.7	(35.7)
Kadcyla	1.8	2.2	2.2	2.3	2.0	+11.1	2.4	+9.1	2.4	+9.1	2.2	(4.3)
Xeloda	2.8	3.3	3.1	3.3	2.4	(14.3)	2.3	(30.3)	1.8	(41.9)	1.6	(51.5)
Tarceva	1.9	2.5	2.1	1.8	1.2	(36.8)	1.3	(48.0)	1.0	(52.4)	1.0	(44.4)
Gazyva	-	-	0.1	0.5	0.6	-	0.9	-	1.0	+900.0	1.1	+120.0
Alaglio	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.0	0.1	0.0
Rozlytrek	-	-	-	-	-	-	-	-	0.0	-	0.0	-
Other products	0.8	1.0	1.4	1.4	0.9	+12.5	1.3	+30.0	2.5	+78.6	1.9	+35.7
<b>Bone and joint diseases</b>	21.6	25.4	25.4	28.0	24.2	+12.0	27.9	+9.8	28.5	+12.2	27.9	(0.4)
Actemra	8.0	9.6	9.8	10.7	9.0	+12.5	10.8	+12.5	11.2	+14.3	10.8	+0.9
Edirol	7.0	8.2	8.3	9.4	8.0	+14.3	9.3	+13.4	9.8	+18.1	9.6	+2.1
Bonviva	2.1	2.4	2.3	2.6	2.3	+9.5	2.5	+4.2	2.4	+4.3	2.4	(7.7)
Suvenyl	1.7	2.0	1.9	2.1	1.7	0.0	1.9	(5.0)	1.9	0.0	1.8	(14.3)
Other products	2.9	3.1	3.1	3.2	3.2	+10.3	3.4	+9.7	3.1	0.0	3.3	+3.1
<b>Renal diseases</b>	8.0	9.0	9.3	10.0	7.9	(1.3)	9.3	+3.3	8.7	(6.5)	8.7	(13.0)
Mircera	4.9	5.8	5.9	6.5	5.0	+2.0	6.0	+3.4	5.6	(5.1)	5.6	(13.8)
Oxarol	1.7	1.8	1.8	2.0	1.6	(5.9)	1.8	0.0	1.7	(5.6)	1.8	(10.0)
Other products	1.4	1.4	1.5	1.5	1.3	(7.1)	1.4	0.0	1.4	(6.7)	1.3	(13.3)
<b>Others</b>	14.6	6.8	7.3	8.7	15.2	+4.1	11.0	+61.8	12.1	+65.8	15.7	+80.5
Hemlibra	-	0.5	1.0	1.5	2.7	-	6.3	+1,160.0	7.8	+680.0	8.4	+460.0
CellCept	2.0	2.3	2.2	2.4	2.2	+10.0	2.5	+8.7	2.3	+4.5	2.4	0.0
Tamiflu(Ordinary use)	8.3	0.0	0.0	1.8	4.7	(43.4)	0.1	-	(0.2)	-	2.7	+50.0
Tamiflu(Govt. stockpiles etc.)	0.1	-	0.4	-	3.2	+3,100.0	-	-	0.1	(75.0)	-	-
Foundation Medicine	-	-	-	-	-	-	0.0	-	0.1	-	0.3	-
Other products	4.2	4.0	3.6	3.0	2.5	(40.5)	2.2	(45.0)	2.1	(41.7)	1.9	(36.7)
<b>Overseas</b>	31.9	32.6	33.5	30.0	38.4	+20.4	34.0	+4.3	43.6	+30.1	35.3	+17.7
<b>Actemra</b>	23.4	21.5	19.6	16.1	25.3	+8.1	18.2	(15.3)	23.7	+20.9	21.1	+31.1
To Roche	23.0	21.0	19.1	15.6	24.9	+8.3	17.7	(15.7)	23.2	+21.5	20.6	+32.1
<b>Alecensa</b>	3.8	6.5	9.3	10.0	8.4	+121.1	11.5	+76.9	14.8	+59.1	10.6	+6.0
To Roche	3.7	6.3	9.1	9.8	8.2	+121.6	11.2	+77.8	14.7	+61.5	10.4	+6.1
<b>Neutrogen</b>	3.0	2.7	3.0	2.4	2.5	(16.7)	2.5	(7.4)	2.6	(13.3)	2.4	0.0
<b>Hemlibra</b>	0.7	0.5	0.8	0.4	0.7	0.0	0.9	+80.0	1.5	+87.5	0.5	+25.0
To Roche	0.7	0.5	0.8	0.4	0.7	0.0	0.9	+80.0	1.5	+87.5	0.2	(50.0)
<b>Other products</b>	1.0	1.4	0.8	1.1	1.4	+40.0	1.0	(28.6)	1.0	+25.0	0.8	(27.3)
<b>Royalties and other operating income</b>	22.7	6.8	8.2	14.2	16.6	(26.9)	21.3	+213.2	30.5	+272.0	28.9	+103.5
<b>Royalty and profit-sharing income</b>	5.0	5.1	5.7	8.3	13.7	+174.0	16.6	+225.5	18.5	+224.6	27.7	+233.7
<b>Other operating income</b>	17.7	1.8	2.5	5.9	2.9	(83.6)	4.7	+161.1	12.0	+380.0	1.1	(81.4)
<b>Revenues</b>	147.4	137.7	141.3	153.3	154.3	+4.7	166.0	+20.6	188.6	+33.5	177.3	+15.7
<b>Domestic</b>	110.6	99.8	102.1	109.0	99.3	(10.2)	111.8	+12.0	118.7	+16.3	114.2	+4.8
<b>Overseas</b>	36.9	37.9	39.2	44.3	55.0	+49.1	54.2	+43.0	69.9	+78.3	63.2	+42.7

"Sales of Tamiflu", which was disclosed separately up to FY 2018, is included in "Sales of Domestic" from the first quarter in FY 2019.

"Royalties and other operating income" is disclosed separately as "Royalty and profit-sharing income" and "Other operating income" from the first quarter in FY 2019.

In the forecast for FY2020, sales of Tarceva and Alaglio are included in "Other products - Oncology". And sales of Suvenyl is included in "Other products - Renal diseases".

## Statements of revenues (YTD)

(Billions of yen)

	Actual	Actual				Actual								Forecast (Jan 30th announced)	
	FY2017	FY2018				FY2019								FY2020	
	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-12	Change (%)
	YTD	YTD	YTD	YTD	YTD	YTD	(%)	YTD	(%)	YTD	(%)	YTD	(%)	YTD	(%)
<b>Sales</b>	499.3	124.7	255.6	388.7	527.8	137.7	+10.4	282.4	+10.5	440.5	+13.3	588.9	+11.6	580.0	(1.5)
Domestic	405.3	92.9	191.1	290.8	399.9	99.3	+6.9	210.0	+9.9	324.4	+11.6	437.6	+9.4	411.6	(5.9)
Oncology	225.9	48.6	105.7	163.3	225.7	52.0	+7.0	114.6	+8.4	179.7	+10.0	240.5	+6.6	228.8	(4.9)
Avastin	93.1	21.0	45.4	69.5	95.6	21.4	+1.9	46.7	+2.9	73.0	+5.0	95.6	0.0	73.3	(23.3)
Perjeta	13.6	3.2	7.0	11.0	16.1	5.6	+75.0	13.2	+88.6	22.0	+100.0	30.7	+90.7	28.8	(6.2)
Herceptin	33.6	6.8	13.8	20.6	28.1	6.2	(8.8)	13.6	(1.4)	20.3	(1.5)	26.7	(5.0)	19.2	(28.1)
Alecensa	16.7	4.0	9.4	14.7	20.6	4.9	+22.5	11.1	+18.1	17.2	+17.0	23.0	+11.7	24.8	+7.8
Tecentriq	-	-	1.7	5.0	9.1	3.7	-	8.2	+382.4	13.7	+174.0	20.6	+126.4	44.6	+116.5
Rituxan	33.4	6.2	11.9	17.0	21.3	3.1	(50.0)	6.4	(46.2)	9.2	(45.9)	11.9	(44.1)	6.3	(47.1)
Kadcyla	8.0	1.8	4.0	6.2	8.5	2.0	+11.1	4.4	+10.0	6.8	+9.7	9.0	+5.9	11.7	+30.0
Xeloda	12.2	2.8	6.1	9.2	12.5	2.4	(14.3)	4.7	(23.0)	6.4	(30.4)	8.0	(36.0)	3.1	(61.3)
Tarceva	10.5	1.9	4.4	6.5	8.3	1.2	(36.8)	2.5	(43.2)	3.5	(46.2)	4.5	(45.8)	-	-
Gazyva	-	-	-	0.1	0.6	0.6	-	1.5	-	2.5	+2,400.0	3.6	+500.0	5.4	+50.0
Alagio	0.0	0.1	0.1	0.2	0.3	0.1	0.0	0.1	0.0	0.2	0.0	0.3	0.0	-	-
Rozlytrek	-	-	-	-	-	-	-	-	-	0.0	-	0.0	-	1.0	-
Other products	4.7	0.8	1.8	3.3	4.7	0.9	+12.5	2.2	+22.2	4.7	+42.4	6.5	+38.3	10.5	+61.5
Bone and joint diseases	93.3	21.6	47.0	72.4	100.5	24.2	+12.0	52.0	+10.6	80.5	+11.2	108.4	+7.9	90.1	(16.9)
Actemra	33.1	8.0	17.7	27.4	38.2	9.0	+12.5	19.8	+11.9	31.0	+13.1	41.8	+9.4	38.2	(8.6)
Edirol	29.6	7.0	15.2	23.4	32.9	8.0	+14.3	17.3	+13.8	27.1	+15.8	36.7	+11.6	26.1	(28.9)
Bonviva	8.7	2.1	4.4	6.8	9.4	2.3	+9.5	4.8	+9.1	7.2	+5.9	9.7	+3.2	9.7	0.0
Suvenyl	8.8	1.7	3.7	5.7	7.8	1.7	0.0	3.6	(2.7)	5.5	(3.5)	7.2	(7.7)	-	-
Other products	13.1	2.9	6.0	9.1	12.3	3.2	+10.3	6.6	+10.0	9.7	+6.6	13.0	+5.7	16.0	+23.1
Renal diseases	39.3	8.0	17.0	26.3	36.3	7.9	(1.3)	17.2	+1.2	25.9	(1.5)	34.6	(4.7)	24.7	(28.6)
Mirceria	23.9	4.9	10.6	16.6	23.1	5.0	+2.0	11.0	+3.8	16.6	0.0	22.2	(3.9)	15.4	(30.6)
Oxarol	8.2	1.7	3.5	5.3	7.3	1.6	(5.9)	3.4	(2.9)	5.2	(1.9)	6.9	(5.5)	5.2	(24.6)
Other products	7.2	1.4	2.8	4.3	5.9	1.3	(7.1)	2.7	(3.6)	4.1	(4.7)	5.4	(8.5)	4.1	(24.1)
Others	46.8	14.6	21.5	28.8	37.5	15.2	+4.1	26.2	+21.9	38.4	+33.3	54.1	+44.3	68.0	+25.7
Hemlibra	-	-	0.5	1.5	3.0	2.7	-	9.0	+1,700.0	16.8	+1,020.0	25.2	+740.0	42.1	+67.1
CellCept	8.9	2.0	4.3	6.6	9.0	2.2	+10.0	4.6	+7.0	6.9	+4.5	9.3	+3.3	8.4	(9.7)
Tamiflu(Ordinary use)	11.9	8.3	8.3	8.3	10.1	4.7	(43.4)	4.8	(42.2)	4.7	(43.4)	7.4	(26.7)	3.4	(54.1)
Tamiflu(Govt. stockpiles etc.)	5.0	0.1	0.1	0.5	0.5	3.2	+3,100.0	3.2	+3,100.0	3.2	+540.0	3.2	+540.0	3.2	0.0
Foundation Medicine	-	-	-	-	-	-	-	0.0	-	0.1	-	0.4	-	4.5	+1,025.0
Other products	21.0	4.2	8.2	11.9	14.9	2.5	(40.5)	4.6	(43.9)	6.7	(43.7)	8.6	(42.3)	6.5	(24.4)
Overseas	94.0	31.9	64.5	97.9	127.9	38.4	+20.4	72.4	+12.2	116.0	+18.5	151.3	+18.3	168.4	+11.3
Actemra	60.9	23.4	44.9	64.4	80.6	25.3	+8.1	43.5	(3.1)	67.2	+4.3	88.3	+9.6	90.8	+2.8
To Roche	59.4	23.0	44.1	63.1	78.7	24.9	+8.3	42.6	(3.4)	65.8	+4.3	86.5	+9.9	88.8	+2.7
Alecensa	13.9	3.8	10.3	19.5	29.5	8.4	+121.1	19.9	+93.2	34.8	+78.5	45.3	+53.6	39.0	(13.9)
To Roche	13.9	3.7	10.0	19.1	28.9	8.2	+121.6	19.4	+94.0	34.1	+78.5	44.6	+54.3	37.8	(15.2)
Neutrogen	12.3	3.0	5.7	8.7	11.1	2.5	(16.7)	5.0	(12.3)	7.6	(12.6)	9.9	(10.8)	9.1	(8.1)
Hemlibra	3.1	0.7	1.2	2.0	2.3	0.7	0.0	1.6	+33.3	3.1	+55.0	3.6	+56.5	23.9	+563.9
To Roche	3.1	0.7	1.2	2.0	2.3	0.7	0.0	1.6	+33.3	3.1	+55.0	3.3	+43.5	23.0	+597.0
Other products	3.9	1.0	2.4	3.3	4.4	1.4	+40.0	2.4	0.0	3.4	+3.0	4.2	(4.5)	5.6	+33.3
Royalties and other operating income	34.9	22.7	29.5	37.7	51.9	16.6	(26.9)	37.9	+28.5	68.4	+81.4	97.3	+87.5	160.0	+64.4
Royalty and profit-sharing income	17.2	5.0	10.1	15.8	24.1	13.7	+174.0	30.2	+199.0	48.8	+208.9	76.5	+217.4	141.0	+84.3
Other operating income	17.7	17.7	19.5	21.9	27.9	2.9	(83.6)	7.6	(61.0)	19.6	(10.5)	20.8	(25.4)	19.0	(8.7)
<b>Revenues</b>	534.2	147.4	285.1	426.4	579.8	154.3	+4.7	320.3	+12.3	508.9	+19.3	686.2	+18.4	740.0	+7.8
Domestic	410.9	110.6	210.3	312.5	421.5	99.3	(10.2)	211.2	+0.4	329.9	+5.6	444.0	+5.3	421.3	(5.1)
Overseas	123.3	36.9	74.8	114.0	158.3	55.0	+49.1	109.1	+45.9	179.0	+57.0	242.2	+53.0	318.6	+31.5

"Sales of Tamiflu", which was disclosed separately up to FY 2018, is included in "Sales of Domestic" from the first quarter in FY 2019.

"Royalties and other operating income" is disclosed separately as "Royalty and profit-sharing income" and "Other operating income" from the first quarter in FY 2019.

In the forecast for FY2020, sales of Tarceva and Alagio are included in "Other products - Oncology". And sales of Suvenyl is included in "Other products - Renal diseases".

## Financial position

(Billions of yen)

	Actual	Actual				Actual										
	FY2017	FY2018				FY2019										
	Dec. 31	Mar. 31	Jun. 30	Sep. 30	Dec. 31	Mar. 31	vs. Mar. 31, 2018	vs. Dec. 31, 2018	Jun. 30	vs. Jun. 30, 2018	vs. Dec. 31, 2018	Sep. 30	vs. Sep. 30, 2018	vs. Dec. 31, 2018	Dec. 31	vs. Dec. 31, 2018
Trade accounts receivable	148.5	137.1	140.6	145.7	150.8	149.6	12.5	(1.2)	154.9	14.3	4.1	161.3	15.6	10.5	139.6	(11.2)
Inventories	169.1	168.1	170.0	163.8	159.4	168.7	0.6	9.3	167.7	(2.3)	8.3	169.0	5.2	9.6	168.1	8.7
Trade accounts payable	(38.4)	(48.7)	(46.2)	(42.3)	(35.9)	(54.9)	(6.2)	(19.0)	(44.8)	1.4	(8.9)	(55.0)	(12.7)	(19.1)	(47.7)	(11.8)
Other net working capital	(28.4)	(24.7)	(18.2)	(28.7)	(39.1)	(19.1)	5.6	20.0	(33.1)	(14.9)	6.0	(35.8)	(7.1)	3.3	(22.9)	16.2
Net working capital	250.7	231.8	246.3	238.5	235.1	244.3	12.5	9.2	244.6	(1.7)	9.5	239.4	0.9	4.3	237.2	2.1
Property, plant and equipment	171.6	174.6	179.2	187.6	222.4	222.1	47.5	(0.3)	243.8	64.6	21.4	247.9	60.3	25.5	255.6	33.2
Right-of-use assets	-	-	-	-	-	12.5	12.5	12.5	11.5	11.5	11.5	10.4	10.4	10.4	9.7	9.7
Intangible assets	21.1	17.9	18.1	19.8	22.7	21.9	4.0	(0.8)	22.4	4.3	(0.3)	22.4	2.6	(0.3)	23.5	0.8
Other long-term assets - net	(3.1)	13.2	12.4	16.9	25.1	27.9	14.7	2.8	27.7	15.3	2.6	28.0	11.1	2.9	21.0	(4.1)
Long-term net operating assets	189.5	205.7	209.6	224.3	270.1	284.3	78.6	14.2	305.5	95.9	35.4	308.7	84.4	38.6	309.8	39.7
Net operating assets	440.2	437.5	455.9	462.7	505.3	528.6	91.1	23.3	550.1	94.2	44.8	548.2	85.5	42.9	547.0	41.7
Debt	(0.3)	(0.3)	(0.3)	(0.2)	(0.2)	-	0.3	0.2	-	0.3	0.2	-	0.2	0.2	-	0.2
Marketable securities	104.0	113.8	119.9	122.9	102.5	111.5	(2.3)	9.0	111.9	(8.0)	9.4	109.1	(13.8)	6.6	129.1	26.6
Cash and cash equivalents	139.1	152.8	154.6	146.0	146.9	125.8	(27.0)	(21.1)	149.2	(5.4)	2.3	177.0	31.0	30.1	203.9	57.0
Net cash	242.8	266.3	274.2	268.6	249.2	237.4	(28.9)	(11.8)	261.0	(13.2)	11.8	286.2	17.6	37.0	333.1	83.9
Other non-operating assets - net	9.9	7.6	1.5	8.3	2.1	(5.5)	(13.1)	(7.6)	(18.9)	(20.4)	(21.0)	(21.2)	(29.5)	(23.3)	(26.1)	(28.2)
Net non-operating assets	252.7	273.9	275.7	276.9	251.3	231.8	(42.1)	(19.5)	242.1	(33.6)	(9.2)	265.0	(11.9)	13.7	307.0	55.7
Total net assets	692.9	711.3	731.7	739.6	756.5	760.5	49.2	4.0	792.2	60.5	35.7	813.1	73.5	56.6	854.0	97.5
Total net assets																
Total assets	852.5	852.9	873.3	890.8	919.5	932.2	79.3	12.7	986.6	113.3	67.1	1,025.3	134.5	105.8	1,058.9	139.4
Total liabilities	(159.6)	(141.5)	(141.7)	(151.2)	(163.0)	(171.8)	(30.3)	(8.8)	(194.5)	(52.8)	(31.5)	(212.2)	(61.0)	(49.2)	(204.9)	(41.9)
Attributable to																
Chugai shareholders	691.9	710.1	731.2	739.0	755.9	760.5	50.4	4.6	792.2	61.0	36.3	813.1	74.1	57.2	854.0	98.1
Non-controlling interests	1.0	1.2	0.5	0.7	0.7	-	(1.2)	(0.7)	-	(0.5)	(0.7)	-	(0.7)	(0.7)	-	(0.7)

Trade accounts receivable: trade receivable and notes receivable

Trade accounts payable: trade payable and notes payable

Other net working capital: accrued receivable (other receivable), accrued payable (other payable), accrued expenses (other current liabilities) etc.

Other long-term assets-net: long-term prepaid expenses, long-term provisions etc.

Other non-operating assets-net: deferred income tax assets, current income tax liabilities etc.

Net operating assets (NOA) and Net assets:

The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, "Presentation of Financial Statements." On the other hand, Net operating assets (NOA) and Net assets are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from Net operating assets (NOA) and Net assets of IFRS have been excluded, as the Core results concept only applies to the income statement.

Net operating assets (NOA):

Net operating assets allow for an assessment of the Group's operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital, long-term net operating assets that includes property, plant and equipment, right-of-use assets, intangible assets etc. minus provisions.

IFRS16 'Leases'

From the first quarter of the fiscal year ended 31 December 2019, the Group has implemented IFRS 16 'Leases'. As a result, leased assets, including right-of-use asset, lease receivable and so on totalling ¥ 15.2 billion and lease liabilities totaling ¥ 14.6 billion have been recorded on the balance sheet, effective 1 January 2019.

## Cash flows

(Billions of yen)

	Actual	Actual				Actual			
	FY2017	FY2018				FY2019			
	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12
	YTD								
Operating profit – IFRS basis	98.9	38.4	66.6	97.9	124.3	46.1	95.1	160.9	210.6
Depreciation and impairment of property, plant and equipment	14.6	3.7	7.4	11.1	14.6	3.7	8.8	13.9	19.0
Depreciation and impairment of right-of-use assets	-	-	-	-	-	1.5	3.0	4.6	6.0
Amortization and impairment of intangible assets	5.8	4.6	5.5	5.9	6.8	2.1	3.7	4.4	5.3
Other cash adjustment on operating profit	1.7	0.4	1.0	1.5	1.6	0.8	1.7	3.1	4.3
Operating profit, net of operating cash adjustments	121.0	47.1	80.4	116.4	147.4	54.1	112.3	186.8	245.2
(Increase) decrease in trade accounts receivable	(7.6)	11.4	7.8	2.8	(2.4)	1.2	(4.2)	(10.6)	11.1
(Increase) decrease in inventories	21.1	0.5	(1.9)	4.5	14.2	(9.5)	(8.7)	(10.4)	(9.0)
Increase (decrease) in trade accounts payable	(4.2)	10.3	7.8	3.9	(2.4)	18.9	9.0	19.3	11.8
Change in other net working capital etc.	5.2	(1.7)	(10.8)	(8.5)	(4.8)	(13.2)	(23.2)	(19.8)	(7.7)
Total (increase) decrease in net working capital etc.	14.5	20.5	2.9	2.7	4.5	(2.5)	(27.1)	(21.5)	6.2
Investment in property, plant and equipment	(32.9)	(9.9)	(15.1)	(23.8)	(71.8)	(7.4)	(10.1)	(21.1)	(53.0)
Lease liabilities paid	-	-	-	-	-	(2.2)	(4.5)	(6.6)	(8.9)
Investment in intangible assets	(11.6)	(1.4)	(2.4)	(4.6)	(5.9)	(3.8)	(5.4)	(6.5)	(8.2)
Operating free cash flows	91.0	56.3	65.9	90.7	74.3	38.3	65.3	131.0	181.4
as % of revenues	17.0%	38.2%	23.1%	21.3%	12.8%	24.8%	20.4%	25.7%	26.4%
Treasury activities (interest income/expenses, foreign exchange gains/losses etc.)	1.6	3.4	3.7	3.4	4.3	0.1	(0.8)	2.8	(0.9)
Settlement for transfer pricing taxation	(5.2)	(0.6)	(1.5)	(2.1)	(3.2)	(0.8)	(1.5)	(2.2)	(3.1)
Tax paid	(22.7)	(16.8)	(17.1)	(31.3)	(31.6)	(17.8)	(18.2)	(34.5)	(34.8)
Free cash flows	64.7	42.3	50.9	60.7	43.7	19.7	44.7	97.1	142.6
Dividends paid	(31.0)	(17.9)	(18.0)	(34.9)	(35.8)	(29.9)	(30.1)	(56.2)	(56.4)
Transaction in own equity instruments	0.9	0.2	0.5	0.9	1.0	0.2	0.4	0.5	0.7
Purchase of non-controlling interests	-	-	-	-	-	(1.7)	(2.3)	(2.3)	(2.3)
Net effect of currency translation on net cash	3.2	(1.0)	(2.0)	(0.8)	(2.5)	(0.2)	(0.8)	(2.1)	(0.8)
Net change in net cash	37.9	23.5	31.4	25.8	6.4	(11.8)	11.8	37.0	83.9

Other cash adjustment on operating profit: adjustments for all non-cash income and expense items other than amortization expenses and impairment included in operating profit (such as loss on inventory differences, reserve for doubtful accounts, stock option expenses, loss on asset retirement, and increase/decrease in reserves) as well as all non-operating income and expense cash flows relating to net operating assets (NOA) (including proceeds from the sales of assets and reserve payments).

Operating free cash flow (Operating FCF): pretax cash flow after adjusting changes in working capital and operating investments in assets (tangible and intangible) to "operating profit, net of operating cash adjustments," which shows the company's cash generation ability from operating activities.

Free cash flow (FCF): the ability to generate net cash from a management perspective after deducting tax, dividends, and other payments from operating FCF.

Net change in net cash: dividends paid, increases and decreases in marketable securities and interest-bearing debt, changes in equity are included.

The concepts of operating profit, operating FCF and Net operating assets (NOA) presented in the previous page are mutually consistent.

## IFRS16 'Leases'

From the first quarter of the fiscal year ended 31 December 2019, the Group has implemented IFRS 16 'Leases'. As a result, cash flows in respect of leases previously reported as operating leases are reported as part of cash flows from financing activities.

## Free cash flow (FCF):

The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, "Statement of Cash Flows." FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results concept only applies to the income statement.

## Key Performance indicators

	Units	Actual	Actual				Actual				Forecast (Jan 30th announced)
		2017	2018				2019				2020
		1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	1-12
		As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
<b>Total indicator</b>											
Core return on invested capital (Core ROIC)	%	18.1	7.3	12.1	17.0	21.2	7.0	14.3	23.7	31.9	
Return on invested capital (ROIC)	%	17.3	6.6	11.3	16.2	20.3	6.8	13.2	22.4	30.1	
Ratio of profit to total assets (ROA)	%	8.9	3.3	5.7	8.1	10.5	3.8	7.2	12.0	15.8	
Ratio of equity attributable to Chugai shareholders	%	81.2	83.3	83.7	83.0	82.2	81.6	80.3	79.3	80.6	
Ratio of equity attributable to Chugai shareholders (stock price base)	%	370.1	345.0	364.0	448.4	379.7	446.8	390.6	448.5	521.2	
Price book value ratio (PBR)	times	4.6	4.1	4.3	5.4	4.6	5.5	4.9	5.7	6.5	
Ratio of net income to equity attributable to Chugai shareholders (ROE)	%	10.9	4.0	6.8	9.8	12.8	4.6	8.9	15.0	19.6	
<b>Margin indicator</b>											
ROS	%	19.3	29.0	25.1	24.2	22.5	31.0	32.3	33.6	32.8	37.2
COS ratio (vs. Prod. sales)	%	50.7	50.9	50.3	50.0	49.6	46.3	45.1	45.7	45.0	43.4
M&D cost ratio	%	13.6	10.8	11.6	11.8	12.7	10.0	10.3	10.0	10.7	
R&D cost ratio	%	16.6	14.2	15.4	15.5	16.2	15.3	15.0	14.1	14.9	15.5
G&A cost ratio	%	3.1	2.9	2.7	2.9	3.4	2.4	2.6	2.7	3.0	
<b>Turn over indicator</b>											
Total asset turnover	%	64.4	17.3	33.0	48.9	65.4	16.5	33.4	51.9	68.9	
Working capital turnover	%	122.6	33.6	63.6	94.5	122.6	29.4	59.9	95.3	128.7	
Inventory turnover	Months	8.0	7.9	7.9	7.6	7.3	7.9	7.9	7.5	7.6	
Receivables turnover	Months	3.6	3.3	3.3	3.4	3.4	3.3	3.3	3.3	2.8	
Payables turnover	Months	1.8	2.3	2.1	2.0	1.6	2.6	2.1	2.5	2.2	
Fixed asset turnover	%	289.5	76.6	146.3	213.2	264.9	59.7	119.0	188.1	250.0	
PP&E turnover	%	325.1	85.2	162.6	237.5	294.3	69.4	137.4	216.4	287.3	
Intangible assets turnover	%	2,646.1	757.4	1,456.3	2,087.5	2,648.9	692.3	1,419.3	2,256.5	2,968.0	
<b>Dividend / per stock indicator</b>											
Dividends per share (Half year)	Yen	29				31				48	75
Dividends per share (Year end)	Yen	33				55				92	25
Dividends per share (Full year)	Yen	62				86				140	-
Core earnings per share (diluted)	Yen	138.68	56.52	95.27	135.14	176.42	66.15	137.11	227.06	305.80	122.00
Core payout ratio (%)	%	44.7				48.7				45.8	41.0
Equity per share attributable to Chugai shareholders (BPS)	Yen	1,265.46	1,298.53	1,336.49	1,350.49	1,381.26	1,389.44	1,447.14	1,485.30	1,559.72	
Ratio of dividends to equity attributable to Chugai shareholders (DOE)	%	5.1				6.5				9.5	
<b>Cashflow indicator</b>											
Cash conversion cycle (CCC)	Months	9.7	8.9	9.1	9.0	9.1	8.6	9.1	8.4	8.3	
Net cash turnover period	Months	5.5	5.4	5.8	5.7	5.2	4.6	4.9	5.1	5.8	
<b>Other indicators</b>											
Number of employees		7,372	7,331	7,490	7,475	7,432	7,411	7,531	7,384	7,394	
Investment on property, plant and equipment	Billions of yen	34.3	7.0	14.5	27.9	71.8	3.7	30.8	40.4	54.0	72.5
Depreciation	Billions of yen	14.5	3.7	7.4	11.0	14.6	3.7	7.6	12.7	17.8	21.0
Investment on intangible assets	Billions of yen	8.0	1.4	2.5	4.6	8.5	1.2	3.5	4.1	6.1	
Amortization	Billions of yen	1.8	0.5	1.0	1.5	2.0	0.6	1.2	1.9	2.6	

Core ROIC: Core net operating profit after taxes / Net operating assets (Core ROIC is calculated by using Core Income taxes)

ROIC: Net operating profit after taxes / Net operating assets (Net operating profit after taxes = Operating profit - income taxes)

ROA: Net income / total assets, ROE: Net income attributable for Chugai shareholders / Equity attributable to Chugai shareholders

Total asset turnover: Revenues / Total asset, CCC: [Trade accounts receivable/Sales + (Inventories - Trade accounts payable)/Cost of sales]\* passed months

Net cash turnover period: Net cash/Revenue\* passed months

Core ROIC, ROIC, ROA, ROE, total asset turnover, working capital turnover, fixed asset turnover, PP&E turnover, and intangible assets turnover are not annualized

As a result of IFRS 16 "Leases" implementation, leased assets, including right-of-use asset, lease receivable and so on totalling ¥ 15.2 billion and lease liabilities totalling ¥ 14.6 billion have been recorded on the balance sheet, effective 1 January 2019. The leased assets are included in NOA calculation.

The Adjusted figures are used for calculating average NOA for Core ROIC and ROIC

Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") has resolved to implement a three-for-one stock split of its common stock. The dividend forecast for the fiscal year ending December 31, 2020

presents the amount prior to the stock split for the end of the second quarter and the amount after the stock split for the end of the fiscal year. The annual dividends per share forecast is not stated because the amounts cannot be simply combined due to the implementation of the stock split. When calculated based on the assumption of no stock split, the year-end dividend is ¥75 and the annual dividend per share is ¥150.

Core EPS for the fiscal year ending December 31, 2020 (forecast) presents the amount after the stock split.

**Major capital investments plan**

(The Company)

(Billions of yen)

Facilities (Location)	Description	Planned investment		Fund raising method	Start of construction	Slated completion date
		Total amount	Investment to-date			
Ukima research laboratories (Kita-ku, Tokyo)	Construction of a New Synthetic Research Building to Enhance Process Development for Small and Middle Molecule APIs	4.5	3.1	Self-financing	May 2018	January 2020
Fujieda area (Fujieda City, Shizuoka)	Enhancement of small and middle molecule APIs	18.2	9.0	Self-financing	May 2019	March 2022
Chugai Life Science Park Yokohama (Totsuka-ku, Yokohama-city, Kanagawa)	Research and development of pharmaceuticals	127.3	22.9	Self-financing	June 2019	August 2022

**Development pipeline (as of January 30, 2020)**

Development code	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<b><u>Oncology</u></b>					
RG6268	Solid tumors [ <i>NTRK</i> fusion-positive]	Launched (19/09)	entrectinib Rozlytrek Oral	Roche/Nerviano Medical Sciences	ROS1/TRK inhibitor
	Non-small cell lung cancer (NSCLC) #	Filed (19/03)			
RG7446	Small cell lung cancer #	Approved (19/08)	atezolizumab Tecentriq Injection	Roche Tecentriq	Engineered anti-PD-L1 monoclonal antibody
	Breast cancer #	Approved (19/09)			
	NSCLC (adjuvant) #	Phase III			
	NSCLC (neoadjuvant) #	Phase III			
	Urothelial carcinoma #	Phase III			
	Muscle invasive urothelial carcinoma (adjuvant) #	Phase III			
	Renal cell carcinoma #	Phase III			
	Renal cell carcinoma (adjuvant) #	Phase III			
	Early breast cancer #	Phase III			
	Ovarian cancer #	Phase III			
	Hepatocellular carcinoma #	Phase III			
	Hepatocellular carcinoma (adjuvant) #	Phase III			
	Head and neck carcinoma (adjuvant) #	Phase III			

Development code	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
RG3502	Breast cancer (adjuvant) #	Filed (19/08)	trastuzumab emtansine Kadcyla Injection	Roche Kadcyla	Anti-HER2 antibody-tubulin polymerization inhibitor conjugate
RG435	Renal cell carcinoma #	Phase III (in combination with RG7446)	bevacizumab Avastin Injection	Roche Avastin	Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody
	Hepatocellular carcinoma #	Phase III (in combination with RG7446)			
	Hepatocellular carcinoma (adjuvant) #	Phase III (in combination with RG7446)			
	Small cell lung cancer #	Phase III (in combination with RG7446)			
RG7440	Prostate cancer	Phase III	ipatasertib	Roche/Array BioPharma	AKT inhibitor
	Breast cancer	Phase III	Oral		
RG7596	Diffuse large B-cell lymphoma (DLBCL)	Phase III	polatuzumab vedotin Injection	Roche	Anti-CD79b antibody-drug conjugate
RG6264	Breast cancer (Fixed-dose combination, subcutaneous injection)	Phase III	trastuzumab/pertuzumab Herceptin/Perjeta Injection	Roche Herceptin/Perjeta	Anti-HER2 humanized monoclonal antibody/ HER2 dimerization inhibitory humanized monoclonal antibody
AF802 / RG7853	NSCLC (adjuvant) #	Phase III	alectinib Alecensa Oral	In-house Alecensa (Roche)	ALK inhibitor
GC33	Hepatocellular carcinoma	Phase I	codrituzumab Injection	In-house	Anti-Glypican-3 humanized monoclonal antibody
ERY974	Solid tumors	Phase I	In-house Injection	In-house	Anti-Glypican-3/CD3 bispecific antibody

Development code	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
RG7421	Solid tumors	Phase I	cobimetinib Oral	Roche/Exelixis Cotellic	MEK inhibitor
RG7802	Solid tumors	Phase I	cibisatamab Injection	Roche	Anti-CEA/CD3 bispecific antibody
RG7828	Hematologic tumors	Phase I	mosunetuzumab Injection	Roche	Anti-CD20/CD3 bispecific antibody
RG7461	Solid tumors	Phase I	Injection	Roche	Anti-FAP humanized antibody-engineered IL-2 variant fusion protein
RG6058	Solid tumors	Phase I	Injection	Roche	Anti-TIGIT human monoclonal antibody
<b><u>Bone and Joint Diseases</u></b>					
ED-71	Osteoporosis	Filed (18/02) China	eldecalcitol Edirol Oral	In-house	Activated vitamin D <sub>3</sub> agent
NRD101	Knee osteoarthritis /Shoulder periarthritis	Phase III China	purified sodium hyaluronate Suvenyl Injection	In-house	Sodium hyaluronate
<b><u>Renal Diseases</u></b>					
EOS789	Hyperphosphatemia	Phase I	Oral	In-house	–
<b><u>Autoimmune Diseases</u></b>					
RG7845	Rheumatoid arthritis	Phase I	fenebrutinib Oral	Roche	BTK inhibitor
RG7880	Inflammatory bowel disease	Phase I	Injection	Roche	Human IL-22 fusion protein

Development code	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<b>Neurology</b>					
SA237 / RG6168	Neuromyelitis optica spectrum disorder (NMOSD)	Filed US	satralizumab  Injection	In-house  (Roche)	Anti-IL-6 receptor recycling antibody
		Filed (19/08) EU			
		Filed (19/11) Japan			
RG1450	Alzheimer's disease	Phase III	gantenerumab  Injection	Roche/MorphoSys	Anti-amyloid-beta human monoclonal antibody
RG6042	Huntington's disease	Phase III	  Injection	Roche/Ionis Pharmaceuticals	Antisense oligonucleotide targeting <i>HTT</i> mRNA
RG7916	Spinal muscular atrophy (SMA)	Phase II/III	risdiplam  Oral	Roche/PTC Therapeutics	SMN2 splicing modifier
RG7935	Parkinson's disease	Phase I	prasinezumab  Injection	Roche/Prothena	Anti- $\alpha$ -synuclein monoclonal antibody
GYM329 / RG6237	Neuromuscular disease	Phase I	  Injection	In-house  (Roche)	Anti-latent myostatin sweeping antibody
RG7906	Psychiatric disorders	Phase I	  Oral	Roche	—
RG6100	Alzheimer's disease	Phase I	semorinemab  injection	Roche/AC Immune	Anti-tau humanized monoclonal antibody
RG7314	Autism spectrum disorder	Phase I	balovaptan  Oral	Roche	Vasopressin 1a receptor antagonist
RG6206	Duchenne muscular dystrophy (DMD)	Development discontinued	  Injection	Roche/Bristol-Myers Squibb	Anti-myostatin adnectin

Development code	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<b><u>Other diseases</u></b>					
RG7716	Diabetic macular edema	Phase III	faricimab	Roche	Anti-VEGF/Ang2 bispecific antibody
	Neovascular age related macular degeneration (nAMD)	Phase III	Injection		
SKY59 / RG6107	Paroxysmal nocturnal hemoglobinuria (PNH)	Phase I/II	crovalimab Injection	In-house (Roche)	Anti-C5 recycling antibody
NXT007	Hemophilia A	Phase I/II	Injection	In-house	Anti-FIXa/FX bispecific antibody
PCO371	Hypoparathyroidism	Phase I	Oral	In-house	PTH1 receptor agonist
AMY109	Endometriosis	Phase I	Injection	In-house	—

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

## Changes from the last announcement on October 24, 2019

### Oncology

- RG7446 Phase III (Hepatocellular carcinoma (adjuvant): development started)
- RG435 Phase III (Small cell lung cancer; in combination with RG7446: development started)  
Phase III (Hepatocellular carcinoma (adjuvant); in combination with RG7446: development started)
- RG6058 Phase I (solid tumors: development started)
- RG7461 Phase I (solid tumors: development started)
- CK127 Phase I (solid tumors) → Removed from the pipeline

Neurology

- SA237/RG6168 Phase III (NMOSD) → Filed (Japan)
- RG6206 Phase II/III (Duchenne muscular dystrophy) → Development discontinued

Other diseases

- CIM331 Phase II (Pruritus in dialysis patients) → Removed from the pipeline

**R&D Activities**

For the changes during FY2019 (January 1 – December 31), please refer to page 4 of “CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the fiscal year 2019).”

Changes from January 1 to 30, 2020 are as follows:

Oncology

- We started Phase III multinational study for the anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody RG435 (Product name: Avastin) for the expected indication of small cell lung cancer, in combination with RG7446, in January, 2020.
- We concluded a global licensing agreement with *Verastem Oncology* for Raf and MEK dual inhibitor CKI27 to grant the Company an exclusive worldwide license to manufacture, develop and commercialize CKI27 in January, 2020.

Neurology

- We decided to discontinue the development of the anti-myostatin adnectin RG6206 for Duchenne muscular dystrophy in consideration of the results of Phase II/III multinational study (SPITFIRE).

**Major Chugai originated developments licensed out to 3<sup>rd</sup> party excluding Roche**

Development code in Chugai	Indication	Stage	Generic name Product name Dosage form	Licensee (granted right )	Mode of Action
CIM331	Atopic dermatitis	Phase III (global)	nemolizumab  Injection	Galderma (exclusive global license for the development and marketing excluding Japan and Taiwan)	Anti-IL-31 receptor A humanized monoclonal antibody
		Phase III (domestic)		Maruho (rights for development and marketing in the skin disease area for the Japanese market)	
	Prurigo nodularis	Phase II (global)		Galderma (exclusive global license for the development and marketing excluding Japan and Taiwan)	
OWL833	Type 2 diabetes	Phase I	Oral	Eli Lilly and Company (worldwide development and commercialization rights)	Oral non-peptidic GLP-1 receptor agonist

## Major clinical trials in oncology field

Treatment	Expected Indication	Study design	Study name	Stage	Planned filing year	
RG3502, Kadcyła	Breast cancer (adjuvant)	Kadcyla vs. Herceptin	KATHERINE	Phase III	Filed	
		Kadcyla + Perjeta vs. Herceptin + Perjeta + chemo	KAITLIN	Phase III		
RG7446 (Tecentriq)	NSCLC [1st line]	PD-L1 positive: Tecentriq vs. chemo	IMpower110	Phase III	-	
		TMB* positive: Tecentriq vs. chemo	B-FAST	Phase II/III		
	NSCLC (neoadjuvant)	Chemo ± Tecentriq	IMpower030	Phase III	2021	
	NSCLC (adjuvant)	Tecentriq vs. best supportive care	IMpower010	Phase III	2022 and beyond	
	Small cell lung cancer	Tecentriq + chemo ± Avastin	BEAT-SC	Phase III (domestic)	2022 and beyond	
	Urothelial carcinoma (UC)	Tecentriq ± chemo vs. chemo	IMvigor130	Phase III	2020	
	Muscle invasive UC (adjuvant)	Tecentriq vs. observation	IMvigor010	Phase III	2020	
	Renal cell carcinoma	Tecentriq + Avastin vs. sunitinib	IMmotion151	Phase III	2020	
	Renal cell carcinoma (adjuvant)	Tecentriq	IMmotion010	Phase III	2022 and beyond	
	Breast cancer	TNBC**:	paclitaxel ± Tecentriq	IMpassion131	Phase III	-
		Early breast cancer	TNBC (adjuvant): paclitaxel ± Tecentriq	IMpassion030	Phase III	2021
		TNBC (neoadjuvant): nab-paclitaxel ± Tecentriq	IMpassion031	Phase III		
		HER2+ (neoadjuvant): Herceptin + Perjeta + chemo ± Tecentriq	IMpassion050	Phase III		
	Ovarian cancer	carboplatin + paclitaxel + Avastin ± Tecentriq	IMaGYN050	Phase III	2020	
	Hepatocellular carcinoma	Tecentriq + Avastin vs. sorafenib	IMbrave150	Phase III	2020	
	Hepatocellular carcinoma (adjuvant)	Tecentriq + Avastin vs. active surveillance	IMbrave050	Phase III	2022 and beyond	
Head and neck carcinoma (adjuvant)	Tecentriq	IMvoke010	Phase III	2022 and beyond		
RG7440 (ipatasertib)	Prostate cancer	abiraterone ± RG7440	IPATential150	Phase III	2021	
	Breast cancer	TNBC: paclitaxel ± RG7440 HR+ breast cancer: paclitaxel ± RG7440	IPATunity130	Phase III	2020	
		fulvestrant + palbociclib ± RG7440	IPATunity150	Phase Ib/III		
		PD-L1 negative TNBC: paclitaxel ± Tecentriq ± RG7440 PD-L1 positive TNBC: paclitaxel + Tecentriq ± RG7440	IPATunity170	Phase III		
RG7596 (polatuzumab vedotin)	DLBCL	Rituxan + Chemo ± RG7596	POLARIX	Phase III	2020	
		Rituxan + bendamustine + RG7596	P-DRIVE	Phase II (domestic)		
RG6264	Breast cancer	RG6264 (SC) + chemo vs. Herceptin (IV) + Perjeta (IV) + chemo	FeDeriCa	Phase III	2021	
RG6268 (Rozlytrek)	NSCLC	ROS1 fusion-positive: Rozlytrek	STARTRK2	Phase II	Filed	
AF802, Alecensa	NSCLC (adjuvant)	ALK fusion-positive: Alecensa vs. chemo	ALINA	Phase III	2022 and beyond	

TMB: tumor mutational burden, TNBC: triple negative breast cancer, HR: hormone receptor